The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool

Authors:

Abstract
Background Alkaptonuria (AKU) is a rare, debilitating autosomal recessive disorder affecting tyrosine metabolism. Deficiency of homogentisate 1,2-dioxygenase leads to increased homogentisic acid (HGA) which is deposited as ochronotic pigment. Clinical sequelae include severe early onset osteoarthritis, increased renal and prostate stone formation and cardiac complications. Treatment has been largely based on analgaesia and arthroplasty. The National AKU Centre in Liverpool has been using 2mg nitisinone (NTBC) off-license for all patients in the United Kingdom with AKU and monitoring the tyrosine metabolite profiles. Methods Patients with confirmed AKU are commenced on 2mg dose (alternative days) of NTBC for three months with daily dose thereafter. Metabolite measurement by LC-MS/MS is performed at baseline, day 4, three-months, six-months and one-year post-commencing nitisinone. Thereafter, monitoring and clinical assessments are performed annually. Results Urine HGA concentration decreased from an average baseline 20,557 μmol/24h (95th percentile confidence interval 18,446-22,669 μmol/24h) by on average 95.4% by six months, 94.8% at one year and 94.1% at two year monitoring. A concurrent reduction in serum HGA concentration of 83.2% compared to baseline was also measured. Serum tyrosine increased from normal adult reference interval to a mean±SD of 594±184 μmol /L at year-two monitoring with an increased urinary excretion from 103±81 μmol /24h at baseline to 1,071±726 μmol /24h two years from therapy. Conclusions The data presented is the first longitudinal survey of NTBC use in an NHS service setting and demonstrates the sustained effect of nitisinone on the tyrosine metabolite profile. Keywords Alkaptonuria, nitisinone, tyrosine, inborn errors of metabolism

This publication has 29 references indexed in Scilit: